Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support

H. Mulla, Giles J. Peek, C. Harvey, C. Westrope, Z. Kidy, R. Ramaiah

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Extracorporeal membrane oxygenation (ECMO) is known to affect pharmacokinetics and hence optimum dosing. The aim of this open label, prospective study was to investigate the pharmacokinetics of oseltamivir (prodrug) and oseltamivir carboxylate (active metabolite) during ECMO. Fourteen adult patients with suspected or confirmed H1N1 influenza were enrolled in the study. Oseltamivir 75 mg was enterally administered twice daily and blood samples for pharmacokinetic assessment were taken on day 1 and 5. A multi-compartmental model to describe the pharmacokinetics of oseltamivir and oseltamivir carboxylate was developed using a nonlinear mixed effects modelling approach. The median (range) clearance of oseltamivir carboxylate was 15.8 (4.8-36.6) l/hour, lower than the reported mean value of 21.5 l/hour in healthy adults. The median (range) steady state volume of distribution of oseltamivir carboxylate was 179 (61-436) litres, much greater than healthy adults but similar to previous reports in critically ill patients. Substantial 'between subject' variability in systemic exposure to oseltamivir carboxylate was revealed; median (range) area under the curve and Cmax were 4346 (644-13660) ng/hour/ml and 509 (54- 1277) ng/ml, respectively. Both area under the curve and Cmax were significantly correlated with serum creatinine (r2=0.37, P=0.02 and r2=0.29, P=0.02, respectively). Systemic exposure to oseltamivir carboxylate following the administration of enteral oseltamivir 75 mg twice daily in adult ECMO patients is comparable to those in ambulatory patients and far in excess of concentrations required to maximally inhibit neuraminidase activity of the H1N1 virus. Dosage adjustment for ECMO, per se, appears not to be necessary; however, doses should be reduced in patients with renal dysfunction.

Original languageEnglish (US)
Pages (from-to)66-73
Number of pages8
JournalAnaesthesia and Intensive Care
Volume41
Issue number1
StatePublished - Jan 2013
Externally publishedYes

Fingerprint

Oseltamivir
Extracorporeal Membrane Oxygenation
Critical Illness
Pharmacokinetics
Area Under Curve
H1N1 Subtype Influenza A Virus
Prodrugs
Neuraminidase
Human Influenza
Small Intestine
oseltamivir carboxylate
Creatinine
Prospective Studies
Kidney
Serum

Keywords

  • ECMO
  • H1N1 influenza
  • Neuraminidase inhibitors
  • Pharmacokinetics

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support. / Mulla, H.; Peek, Giles J.; Harvey, C.; Westrope, C.; Kidy, Z.; Ramaiah, R.

In: Anaesthesia and Intensive Care, Vol. 41, No. 1, 01.2013, p. 66-73.

Research output: Contribution to journalArticle

Mulla, H. ; Peek, Giles J. ; Harvey, C. ; Westrope, C. ; Kidy, Z. ; Ramaiah, R. / Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support. In: Anaesthesia and Intensive Care. 2013 ; Vol. 41, No. 1. pp. 66-73.
@article{3d60a40a20214577b6338ea1b50fbd0a,
title = "Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support",
abstract = "Extracorporeal membrane oxygenation (ECMO) is known to affect pharmacokinetics and hence optimum dosing. The aim of this open label, prospective study was to investigate the pharmacokinetics of oseltamivir (prodrug) and oseltamivir carboxylate (active metabolite) during ECMO. Fourteen adult patients with suspected or confirmed H1N1 influenza were enrolled in the study. Oseltamivir 75 mg was enterally administered twice daily and blood samples for pharmacokinetic assessment were taken on day 1 and 5. A multi-compartmental model to describe the pharmacokinetics of oseltamivir and oseltamivir carboxylate was developed using a nonlinear mixed effects modelling approach. The median (range) clearance of oseltamivir carboxylate was 15.8 (4.8-36.6) l/hour, lower than the reported mean value of 21.5 l/hour in healthy adults. The median (range) steady state volume of distribution of oseltamivir carboxylate was 179 (61-436) litres, much greater than healthy adults but similar to previous reports in critically ill patients. Substantial 'between subject' variability in systemic exposure to oseltamivir carboxylate was revealed; median (range) area under the curve and Cmax were 4346 (644-13660) ng/hour/ml and 509 (54- 1277) ng/ml, respectively. Both area under the curve and Cmax were significantly correlated with serum creatinine (r2=0.37, P=0.02 and r2=0.29, P=0.02, respectively). Systemic exposure to oseltamivir carboxylate following the administration of enteral oseltamivir 75 mg twice daily in adult ECMO patients is comparable to those in ambulatory patients and far in excess of concentrations required to maximally inhibit neuraminidase activity of the H1N1 virus. Dosage adjustment for ECMO, per se, appears not to be necessary; however, doses should be reduced in patients with renal dysfunction.",
keywords = "ECMO, H1N1 influenza, Neuraminidase inhibitors, Pharmacokinetics",
author = "H. Mulla and Peek, {Giles J.} and C. Harvey and C. Westrope and Z. Kidy and R. Ramaiah",
year = "2013",
month = "1",
language = "English (US)",
volume = "41",
pages = "66--73",
journal = "Anaesthesia and Intensive Care",
issn = "0310-057X",
publisher = "Australian Society of Anaesthetists",
number = "1",

}

TY - JOUR

T1 - Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support

AU - Mulla, H.

AU - Peek, Giles J.

AU - Harvey, C.

AU - Westrope, C.

AU - Kidy, Z.

AU - Ramaiah, R.

PY - 2013/1

Y1 - 2013/1

N2 - Extracorporeal membrane oxygenation (ECMO) is known to affect pharmacokinetics and hence optimum dosing. The aim of this open label, prospective study was to investigate the pharmacokinetics of oseltamivir (prodrug) and oseltamivir carboxylate (active metabolite) during ECMO. Fourteen adult patients with suspected or confirmed H1N1 influenza were enrolled in the study. Oseltamivir 75 mg was enterally administered twice daily and blood samples for pharmacokinetic assessment were taken on day 1 and 5. A multi-compartmental model to describe the pharmacokinetics of oseltamivir and oseltamivir carboxylate was developed using a nonlinear mixed effects modelling approach. The median (range) clearance of oseltamivir carboxylate was 15.8 (4.8-36.6) l/hour, lower than the reported mean value of 21.5 l/hour in healthy adults. The median (range) steady state volume of distribution of oseltamivir carboxylate was 179 (61-436) litres, much greater than healthy adults but similar to previous reports in critically ill patients. Substantial 'between subject' variability in systemic exposure to oseltamivir carboxylate was revealed; median (range) area under the curve and Cmax were 4346 (644-13660) ng/hour/ml and 509 (54- 1277) ng/ml, respectively. Both area under the curve and Cmax were significantly correlated with serum creatinine (r2=0.37, P=0.02 and r2=0.29, P=0.02, respectively). Systemic exposure to oseltamivir carboxylate following the administration of enteral oseltamivir 75 mg twice daily in adult ECMO patients is comparable to those in ambulatory patients and far in excess of concentrations required to maximally inhibit neuraminidase activity of the H1N1 virus. Dosage adjustment for ECMO, per se, appears not to be necessary; however, doses should be reduced in patients with renal dysfunction.

AB - Extracorporeal membrane oxygenation (ECMO) is known to affect pharmacokinetics and hence optimum dosing. The aim of this open label, prospective study was to investigate the pharmacokinetics of oseltamivir (prodrug) and oseltamivir carboxylate (active metabolite) during ECMO. Fourteen adult patients with suspected or confirmed H1N1 influenza were enrolled in the study. Oseltamivir 75 mg was enterally administered twice daily and blood samples for pharmacokinetic assessment were taken on day 1 and 5. A multi-compartmental model to describe the pharmacokinetics of oseltamivir and oseltamivir carboxylate was developed using a nonlinear mixed effects modelling approach. The median (range) clearance of oseltamivir carboxylate was 15.8 (4.8-36.6) l/hour, lower than the reported mean value of 21.5 l/hour in healthy adults. The median (range) steady state volume of distribution of oseltamivir carboxylate was 179 (61-436) litres, much greater than healthy adults but similar to previous reports in critically ill patients. Substantial 'between subject' variability in systemic exposure to oseltamivir carboxylate was revealed; median (range) area under the curve and Cmax were 4346 (644-13660) ng/hour/ml and 509 (54- 1277) ng/ml, respectively. Both area under the curve and Cmax were significantly correlated with serum creatinine (r2=0.37, P=0.02 and r2=0.29, P=0.02, respectively). Systemic exposure to oseltamivir carboxylate following the administration of enteral oseltamivir 75 mg twice daily in adult ECMO patients is comparable to those in ambulatory patients and far in excess of concentrations required to maximally inhibit neuraminidase activity of the H1N1 virus. Dosage adjustment for ECMO, per se, appears not to be necessary; however, doses should be reduced in patients with renal dysfunction.

KW - ECMO

KW - H1N1 influenza

KW - Neuraminidase inhibitors

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84874408877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874408877&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 66

EP - 73

JO - Anaesthesia and Intensive Care

JF - Anaesthesia and Intensive Care

SN - 0310-057X

IS - 1

ER -